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Canada’s Tri-Council Policy Statement:Ethical conduct for research involvinghumans, first published in 1998, has
recently been updated.1 The US Department of
Health and Human Services has just issued an
Advance Notice of Proposed Rulemaking that
would substantially change the 20-year-old
Common Rule governing most federally funded
research involving human participants.2 A com-
parison of the two countries’ systems for pro-
tecting human research participants is therefore
timely. This analysis situates the Canadian sys-
tem in an international context, with particular
attention to its similarities and differences to
the US system and their shared challenges
going forward with their changes.
Systems of oversight for research
with humans
Prior review of research proposals by a research
ethics committee according to legally binding
standards is the primary means used around the
world to protect research participants. In Canada
and the United States, the institutions that con-
duct research are responsible for its review. As a
result, most academic centres have their own
research ethics committee — a research ethics
board in Canada or an institutional review board
in the US. Similar institutional models are fol-
lowed by other developed countries, such as
Australia and Japan. By contrast, regional mod-
els — in which a research ethics committee
reviews all the research conducted in a particular
geographic area — are common in Europe.
In Canada, any institution that receives fund-
ing from one of the three federal granting agen-
cies — the Canadian Institutes of Health Re -
search, the Social Sciences and Humanities
Research Council, and the Natural Sciences and
Engineering Research Council of Canada —
must ensure that all research involving humans
conducted at that institution complies with the
Tri-Council Policy Statement. Health Canada
also requires that sponsors of clinical trials of
drugs and devices obtain approval from a
research ethics board, and two provinces (Que-
bec, and Newfoundland and Labrador) require
ethics review for some or all of the research that
takes place within them.3,4 However, the Tri-
Council Policy Statement is the primary source
of concrete guidance regarding the ethical over-
sight of research with humans in Canada. From
its inception, the statement has been intended to
be a “living, evolving document that reflects
developments in research and research ethics.”5
Hence the current revisions.
In the US, most research involving human
participants funded by federal government agen-
cies is subject to the Common Rule — a set of
regulations delineating the requirements for
review by an institutional review board.6 Similar
rules apply to research regulated by the Food and
Drug Administration (FDA).7 Although US insti-
tutions could decline to apply the Common Rule
to research that does not receive federal funding,
relatively few do so.8 The reforms proposed in
the recent Advance Notice of Proposed Rule-
making have two goals. First, to improve the
effectiveness of the system of federal oversight,
for example, by reducing the amount of time
spent reviewing low-risk research and by allow-
ing only one institutional review board of record
for multisite studies.9 Second, to enhance protec-
tions for research participants, for example, by
imposing uniform standards of security of data
and requiring all research at institutions receiv-
ing funding from Common Rule agencies to fol-
low the Common Rule (just as the Tri-Council
Policy Statement does for Canada).
In both systems, then, ethics review of research
is necessary if funding is received from the federal
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• The updated Tri-Council Policy Statement has nearly doubled in length
and improves on its 1998 predecessor.
• The recent US Advance Notice of Proposed Rulemaking suggests
substantial changes to the Common Rule. 
• Canada and the United States have similar systems of ethical review
with similar problems.
• The problems that have not been addressed thus far mostly concern
the application and scope of rules, not their content.
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government or regulatory approval of new drugs
and devices is sought. Again, this differs from
many other countries, where all research with
human participants within their borders may be
required to undergo review. For example, the
European Clinical Trials Directive applies to all
clinical trials, irrespective of source of funding or
other contact with government bodies.10
The institutional model of review has the
advantages that members of the research ethics
committee are more likely to be familiar with the
research they review, monitoring of ongoing
research is easier and it is possible to impose
institutional sanctions for violations by investiga-
tors. However, this model has several drawbacks.
First, conflicts of interest are more likely because
the institution hosting the research ethics com-
mittee has an interest in the research proceeding,
and members of the research ethics committee
may be colleagues of the researchers.11 Second,
an increasing amount of research now takes
place at multiple sites.12 In Canada and the US,
because institutions are held liable for regulatory
breaches, this usually entails a research ethics
committee at each site reviewing the research
proposal. Multiple reviews take up time and
resources, and researchers complain of inconsis-
tent judgments from research ethics committees
that mandate minor changes without improving
protections for research participants.13,14
Use of government funding or contact with
regulatory agencies as the way to ensure ethics
review carries the risk of ethically problematic
research falling through the cracks. For example,
pharmaceutical companies may conduct research
that is not part of marketing applications, and
experimentation with surgical techniques may
not use novel drugs or devices. Stories of people
being enrolled in risky research without protec-
tions has led to calls in the US for a nationwide
law requiring ethics review.15,16
This method of ensuring ethics review can
also lead to research falling under multiple sets
of regulations. For example, the US federal gov-
ernment funds a substantial amount of research
involving human participants abroad, including
in Canada (e.g., in 2010 the National Institutes of
Health gave nearly US$64 million in direct
grants to Canadian institutions).17 Because of the
funding source, the researchers must follow the
Common Rule; but at Canadian institutions they
must simultaneously follow the Tri-Council Pol-
icy Statement. The same concern arises when
researchers from Canadian institutions conduct
research abroad.
Where possible, the Tri-Council Policy State-
ment and the Common Rule do attempt to
address these problems. The Tri-Council Policy
Statement has considered conflicts of interest,
including conflicts of interest for members of
research ethics boards, since 1998.18 The updated
statement extends its analysis of conflicts of
interest and the measures that should be taken to
address them, for instance, by addressing con-
flicts of interest for institutions and institutional
officials. With regard to multiple reviews, both
Canadian and US rules permit institutions to rely
on outside research ethics committees, although
relatively few institutions currently use this op -
tion.19 However, experiments with centralizing
review — such as the US National Cancer Insti-
tute’s Central Institutional Review Board and the
Ontario Cancer Research Ethics Board — have
had broadly positive results.20,21 An analysis of
centralized and noncentralized review in five
English-speaking countries suggested that cen-
tralizing at least the administrative aspects of
ethics review is helpful in reducing delays and
excessive work from multisite trials.22 Moreover,
one key change in the US Advance Notice of
Proposed Rulemaking would require there to be
just one institutional review board of record for
all domestic sites involved in a multisite study.
Multijurisdictional research has its own chapter
in the updated Tri-Council Policy Statement,
which includes extensive discussion of a range
of different models for review by research ethics
boards of multisite research.
The problem of having both sets of regula-
tions apply to research in Canada funded by the
US government could also be solved under the
current regulations. For research at institutions in
foreign countries that follow different procedures
for protecting human participants, the Common
Rule states the following:
if a department or agency head determines that the
procedures prescribed by the institution afford protec-
tions that are at least equivalent to those provided in
this policy [the Common Rule], the department or
agency head may approve the substitution of the for-
eign procedures in lieu of the procedural requirements
provided in this policy.23
However, despite the development of a method
for determining whether a set of procedures
offers “equivalent protections,” this option has
never been taken.24  
The problems just noted stem from structural
features of the systems of review. In some in -
stances, documents like the Tri-Council Policy
Statement can be helpful. For example, a future
revision could follow the Advance Notice of Pro-
posed Rulemaking and require that only one
research ethics board conduct most of the review
for multisite studies. In other instances, however,
legislative action would be needed to change the
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systems in ways that would address the prob-
lems. For example, as it stands, the Tri-Council
Policy Statement does all that it can to ensure
that potentially risky research undergoes review
— the Tri-Council agencies do not have the
power to require review at institutions where
they do not fund research. That would require
provincial or national legislation.
The process of ethical review
Like the ethics review systems in other countries,
the Canadian and US systems have provoked
criticism from researchers for inappropriately
applying biomedical models to research from
other disciplines and for requiring low-risk
research to undergo excessive scrutiny.
The Common Rule was written in response to
abuses by biomedical researchers and designed to
regulate biomedical research. Nonetheless, it
applies to any research that involves obtaining
data through “intervention or interaction” with
living persons, and review by institutional review
boards of humanities and social science research
is now common. The Tri-Council Policy State-
ment was explicitly intended to cover nonbio-
medical research. However, in both countries,
some social science researchers complain that a
biomedical model is inappropriately imposed on
their discipline with a potentially chilling effect
on important research.25,26 The updated Tri-Council
Policy Statement places greater emphasis than
its predecessor on distinguishing the standards
that should apply to different types of research;
for example, it now has separate chapters dis-
cussing qualitative research and clinical trials. It
is also the result of an extensive process of con-
sultation, including with academics in the social
and behavioural sciences, and, as a Tri-Council
statement, has been endorsed by the Social Sci-
ences and Humanities Research Council.
Both jurisdictions exempt some research with
humans from review, and countenance an expe-
dited or delegated form of review for some
research involving “minimal risk” whereby the
review is conducted by just one or two members
of a research ethics committee. Nevertheless, full
review by a research ethics committee is com-
mon even for research that falls into one of these
categories.27,28 One of the changes proposed by
the US Advance Notice of Proposed Rulemaking
would attempt to address this problem by excus-
ing a wider category of studies from review,
including all studies whose risks are mostly
informational, provided that they adhere to strict
standards for data security and confidentiality.
Crucially, researchers engaged in excused re -
search would be permitted to begin research
immediately after registering their study with the
institutional review board, so as to avoid the cur-
rent situation where many institutions require
some prior review of purportedly exempt studies
to ensure that they are exempt.
The updated Tri-Council Policy Statement
continues to place more emphasis on flexibility
than the Common Rule (although the Advance
Notice of Proposed Rulemaking offers some
ways to make the scrutiny of research proposals
more proportionate to levels of risk than at pre-
sent). The updated statement consistently em -
phasizes the importance of a “proportionate
approach to research ethics review”29 according
to which the most risky research receives the
“most intensive scrutiny, time and resources.”30
Moreover, individual institutions are granted
considerable leeway in deciding how to institute
this proportionate approach, who may carry out
delegated reviews and so forth. This flexibility is
a model for others to follow, and Canadian insti-
tutions should make the most of it — the re -
sources for ethics review are always limited, so
they should be used to focus on the research
most likely to raise ethical concerns.31
The Tri-Council Policy Statement
Its significantly greater length allows the Tri-
Council Policy Statement to address many more
ethical issues than the Common Rule. Although
guidance on specific questions is periodically
issued by the FDA or the Office for Human
Research Protections, the US does not have reg-
ulatory requirements covering so many key
issues.32 The updated Tri-Council Policy State-
ment mostly consists of changes or additions,
which have nearly doubled its size.33 These in -
clude further guidance on research involving
Aboriginal people, incidental findings relevant to
participants’ health, conflicts of interest and
research during emergencies. The additions
reflect ethical issues that have become much
more prominent over the last decade. The up -
dated statement also casts its net more widely to
cover more than just the protection of research
participants. For instance, like the 2008 Declara-
tion of Helsinki, it now requires the registration
of clinical trials before recruitment begins.34
The core principles of the Tri-Council Policy
Statement have been radically revised. Accord-
ing to the first version of the statement, respect
for human dignity was the foundational principle
of research ethics. Somewhat confusingly, it was
also one of eight guiding ethical principles. The
updated version consolidates these principles to
three — respect for persons, concern for welfare,
and justice. These correspond to the principles
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underlying the US regulations as stated in the
Belmont Report.35 The updated Tri-Council Pol-
icy Statement purports to retain “respect for
human dignity” as its “underlying value.” How-
ever, the concept does not do any real work inde-
pendent of the core principles.
The new approach is an improvement: the three
principles better reflect the content of ordinary
moral thought. Ethical dilemmas that people face
in all areas of life — not just in research — involve
the consideration of how to respect people’s rights,
balance benefits and harms, and treat people fairly.
Moreover, none of these three principles can be
assimilated to any of the others; for example, it is
important to respect someone’s autonomous deci-
sions, even if they are likely to negatively affect his
or her welfare. Hence, these three principles are
both central and basic to moral thought.
Substantive disagreements
The original Tri-Council Policy Statement and
the US regulations differed on several issues,
most notably on the use of placebo controls and
research with children. These disagreements
remain. The US FDA permits placebo controls
even when there exists an effective treatment for
the condition being studied in a wide range of
cases in which use of placebo is deemed scien-
tifically necessary.36 The updated Tri-Council
Policy Statement is much more restrictive. The
only instance it suggests in which it would be
permissible to randomly assign participants to
placebo when a proven treatment for those par-
ticipants exists is when “patients have provided
an informed refusal of established effective ther-
apy” before recruitment.37 This is strict in com-
parison to even the Declaration of Helsinki,
which now allows the use of placebos when an
effective treatment exists if there are “com-
pelling and scientifically sound methodological
reasons” for using placebo, and participants will
not be at risk of serious harm.38 
The updated Tri-Council Policy Statement
permits research with children only when it
poses minimal net risk to participants. This is
consistent with international guidelines such as
the Declaration of Helsinki.39 In the US, children
may be enrolled in research that involves a
“minor increase over minimal risk” with no
prospect of direct benefit if the research is ex -
pected to produce important knowledge about
the participants’ disorder or condition.40 There is
even provision for the approval of riskier re -
search in exceptional circumstances.41
With these rules strictly applied, one would
expect these differences to lead to different
research being conducted in the two countries
and to impede some collaborative research. If
they have not, it might illuminate the practice of
review by research ethics committees to investi-
gate why.
Looking forward
The updated Tri-Council Policy Statement
improves on the guidance of its predecessor and
expands on ethical issues that were less promi-
nent in 1998. It should also prove a useful
resource in the US, where institutional review
boards sometimes lack clear guidance on the
novel ethical issues they face. However, the
biggest problems for both systems concern the
implementation of the rules, not their content.
Many of these problems — such as conflicts of
interest in research ethics committees, underre-
view and overreview — are related to the insti-
tution-based model of ethical review in both
countries. For the most part, guidance and regu-
latory resources, like the Tri-Council Policy
Statement, address these problems, but their
suggested solutions require work by institutions
and government agencies to implement them
effectively. Either greater efforts to implement
them are needed, or stricter rules — like those
now proposed for multisite review in the US —
must be imposed.
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